Companies › Annexon
2 active drug programs in 2 registered trials: 2 Phase 3; Ophthalmology, Neurology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tanruprubart (ANX005) C3 complement inhibitor | C3 | Phase 3 | Guillain-Barre Syndrome | May 2027 |
| Vonaprument (ANX007) Complement 3 (C3) inhibitor | C3 | Phase 3 | Geographic Atrophy | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07020819 | Tanruprubart (ANX005) | Phase 3 | Guillain-Barre Syndrome | Neurology | May 2027 |
| NCT06510816 | Vonaprument (ANX007) | Phase 3 | Geographic Atrophy | Ophthalmology | Jul 2027 |
Cash and short-term investments of $213m on 2026-09-30; operating cash outflow about $193m a year; runway about 13 months at that burn, to Nov 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Oculis NervGen Pharma Immunic Alpha Cognition Immunovant Sciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.